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ABSTRACT
Background. Endocrine therapy initiation after ductal carci-
noma in situ (DCIS) is highly variable and largely unexplained.
National guidelines recommend considering tamoxifen for
women with estrogen receptor-positive (ER1) DCIS or who
undergo excision alone.We evaluated endocrine therapy use
after DCIS over a 15-year period in an integrated health care
setting to identify factors related to initiation.
Methods. Female Group Health Cooperative enrollees ages
18–89yearswithaDCISdiagnosisduring1996–2011wereeligible
for inclusion.Endocrinetherapywas identifiedthroughpharmacy
records. Tumor and treatment information were from tumor
registry reports; demographics and other risk factors were from
questionnairesandelectronicmedicalrecords.Relativerisks(RRs)
and95%confidenceintervals(CIs) forendocrinetherapyinitiation
were calculated using multivariable generalized linear models.
Results.We identified 727 women with a DCIS diagnosis,
including 163 (22%) who initiated endocrine therapy (149
tamoxifen, 14 aromatase inhibitor). Younger women were
more likely to initiate endocrine therapy (RR 1.69; 95%
CI 1.16–2.46 for ages 45–54 vs. 65–74 years). Compared
with breast-conserving surgery (BCS) with radiation, women
whohadBCS alone (RR0.46; 95%CI 0.25–0.84) ormastectomy
(RR 0.54; 95% CI 0.39–0.75) were less likely to use endocrine
therapy. ER testing increased from 4% of DCIS cases in 2001 to
71% in 2011; however, endocrine therapy initiation decreased
from 58% of ER1 DCIS in 2001–2005 to 37% in 2009–2011.
Conclusion. Increasing ER testing since 2001 has not corre-
sponded to parallel increases in endocrine therapy initiation.
Age, surgery, and radiation were the primary factors as-
sociated with initiation. The Oncologist 2016;21:134–140
Implications for Practice:National guidelines recommend considering tamoxifen for women with ductal carcinoma in situ (DCIS)
who are estrogen receptor-positive (ER1) or who undergo excision alone. In this study, the rapid increase in ER testing caused by
tamoxifen’s approval in 2000did not lead to increases in endocrine therapy initiation, despite recognition of an increasing number
of DCIS tumors as ER1 each year. Contrary to the suggested guidelines, women who had breast-conserving surgery without
radiation were less likely to use tamoxifen than those who had radiation. Future Food and Drug Administration approval of new
endocrine agents for DCIS (such as aromatase inhibitors) may provide an opportunity to reemphasize benefits by ER and surgery
status.
INTRODUCTION
Ductal carcinoma in situ (DCIS) is a stage 0 breast cancer that is
frequently detected by mammogram and accounts for.20%
of all breast cancer diagnoses [1].The standard of care for DCIS
is breast-conserving surgery (BCS) with radiation or mastec-
tomy [2], and 10-year survival exceeds 97% [3]. Mastectomy
maybe recommended forwomenwithmultifocal disease, and
approximately 5%ofwomenwith aDCISdiagnosis also elect to
have a contralateral prophylactic mastectomy [4].
Tamoxifen was approved by the Food and Drug Adminis-
tration (FDA)asadjuvantendocrine therapyforDCIS in2000. In
the placebo-controlled National Surgical Adjuvant Breast and
Bowel Project (NSABP)-B24 trial, tamoxifen reduced the riskof
ipsilateral and contralateral second events by 30% and 52%,
respectively, when added to BCS and radiation (relative risk
[RR] 0.70; 95%confidence interval (CI) 0.50–0.98, andRR0.48;
95% CI 0.26–0.87, respectively) [5]. In a reanalysis of a subset
of 732 participants with estrogen receptor (ER) expression
information, this benefit was most apparent among women
with ER1 DCIS (hazard ratio [HR] 0.58; 95% CI 0.42–0.81
compared with HR 0.88; 95% CI 0.49–1.59 for women with ER2
DCIS) [6]. Current National Comprehensive Cancer Network
guidelines recommend ER testing for DCIS patients and con-
sideration of tamoxifen for women with ER1 disease or who
undergo BCS without radiation [2].
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Providers and women must weigh the benefits of tamox-
ifen for reducing second breast cancer events and improving
bone health (in postmenopausal women) against an increased
risk of cataract, endometrial cancer, stroke, deep vein thrombo-
sis, pulmonary embolism, and potentially severe vasomotor and
gynecologic symptoms [7]. No mortality benefit for tamoxifen
after DCIS has been conclusively demonstrated [8, 9], although
predictive models estimate a 2- to 6-month survival benefit
fromaddingtamoxifen toBCSandradiationafterDCISanda2- to
5-month benefit of adding tamoxifen to BCS alone [10].
Striking differences in tamoxifen initiation among women
with a DCIS diagnosis—from 30% to 70% across National
Comprehensive Cancer Network centers [11]—are largely
unexplained. Variation in tamoxifen use may be driven by
patterns in ER testing, concurrent treatment decisions, de-
mographics, or other factors. Few studies have had information
available on ER testing or personal characteristics that may
affect the side-effect profile of tamoxifen, including prior
hysterectomy, clotting events, or smoking status, to address
characteristics associated with initiation. To identify factors
that contribute to tamoxifen initiation, we evaluated tamoxifen
use after DCIS diagnosis over a 15-year period in an integrated
health care settingwith detailed treatment andmedical history
information.
METHODS
We conducted a retrospective cohort study of womenwith an
incident diagnosis of breast carcinoma in situ (American Joint
Committee on Cancer stage 0) during 1996–2011 at ages
18–89 years. Among the 1,145 women identified, eligibility
criteria required continuous enrollment in Group Health
Cooperative for 12 months before and 12 months after
diagnosis (n 5 789, 69%), except in the case of death. DCIS
diagnoseswere further limited to histologic codes 8201, 8230,
8500, 8501, 8503, 8507, 8522, 8523, and 8543. The final
analytic sample included 727 women. All study procedures,
including a waiver of consent to review electronic data and
abstract medical records, were approved by the institutional
review board at Group Health Cooperative Research Institute.
Data Collection
All women received care at facilities owned and operated
by Group Health Cooperative, which serves approximately
600,000 residents of Washington State.Western Washington
Surveillance, Epidemiology, and EndResults registrydatawere
used to identify diagnosis dates, race/ethnicity, tumor size,
comedo status, breast surgery, and radiation therapy. Group
Health enrollee records have been linked with the registry
annually since1974.Risk factor information suchaseducation,
body mass index, and smoking status were prospectively
collected from women before diagnosis as part of the Group
Health Breast Cancer Surveillance project [12, 13]. Hysterec-
tomy status was available from an up-to-date clinical data-
base [14] that is maintained to identify women who are not
recommended for cervical cancer screening.Osteoporosis and
related fractures (733.00–733.03, 733.09, 820–821, 805,
807–807.4, 807.7–808, 810–814, 823–824), deep vein throm-
bosis (451.1, 451.2, 451.81, 451.9, 453.0, 453.2, 453.4, 453.8,
453.9), pulmonary embolism (415.1, 415.11–415.13, 415.19,
416.2, 453.1, 453.2, 453.9, 673.2, 639.6), and stroke (430, 431,
432.9, 434, 436, 432.0–432.1) were identified from Interna-
tional Classification of Disease, Ninth Revision codes before
diagnosis.The Charlson Comorbidity Index [15]was calculated
using diagnosis and procedure codes in electronic and
administrative databases in the 12 months before diagnosis.
Detailed electronic administrative data provided informa-
tion on outpatient pharmacy dispensing, including use of
osteoporosis medications and adjuvant endocrine therapy.
We defined endocrine therapy initiation as the first phar-
macy fill record for tamoxifen or an aromatase inhibitor within
12 months after diagnosis [16]. Aromatase inhibitors (AIs)
were included to capture potential off-label use. GroupHealth
electronic pharmacydatahas been shown to be97%complete
[17, 18]; pharmacy records are captured for all Group Health
enrollees who fill prescriptions at Group Health pharmacies
and for all Group Health enrollees with a drug benefit who fill
prescriptions at outside pharmacies.
Statistical Analysis
We used multivariable generalized linear models with a log
link, Poisson distribution, and robust SEs to estimate RRs for
endocrine therapy initiation [19].We assessed race, ER status,
breast surgery and radiation, tumorgrade, tumor size, comedo
status, calendar yearofdiagnosis, education, bodymass index,
smoking status, hysterectomy, comorbidity index, and history
of osteoporosis, fracture, deep vein thrombosis, pulmonary
embolism, and stroke as potential confounders in age-
adjustedmodels. Age adjustmentwas performedwith indicator
variables for the following ages at diagnosis: 18–44, 45–54,
55–64, 65–74, and 75–89 years. Final multivariable models
included adjustment for the following covariates: age, calendar
year of diagnosis (1996–2000, 2001–2005, 2006–2008, and
2009–2011), ER status (positive, negative, and unknown/not
tested), surgery and radiation (BCS without radiation, BCS with
radiation, and mastectomy), grade (I–II [well to moderately
differentiated] and III [poorly differentiated]), tumor size (#5,
6–14, 15–24, $25 mm, and unknown/not documented),
comedo status (presence or absence of comedo necrosis),
and education (high school or less, some college, and
college diploma or more). All analyses were performed with
SAS 9.3 (SAS Institute, Cary, NC, https://www.sas.com/
en_us/home.html).
RESULTS
Among 727 women with a DCIS diagnosis, the average age
at diagnosis was 60.2 years (SD 11.9, range 28–89). Overall,
our sample was 87% white, 9% Asian/Pacific Islander, and 4%
black and mirrored the racial demographics of Washington
State and the Seattle area [20]. Fewer than 2%ofwomenwere
of Hispanic or Spanish ethnicity. The majority of women
had attended at least some college (77%), had a body mass
index .25 kg/m2 (58%), and reported never smoking (60%).
Approximately one quarter of thewomen in our sample (26%)
had a hysterectomy before diagnosis.
After diagnosis, 149 (21%) women initiated tamoxifen and
14 (2%) an aromatase inhibitor (total n 5 163, 22%). Among
womenwho initiated tamoxifen, 91%filledat least2 tamoxifen
prescriptions during the 12 months after diagnosis. The
average time to first tamoxifen fill was 130days fromdiagnosis
(median129days; interquartile range84–168days).Thirty-one
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women (4%) had an order record for either tamoxifen or an
aromatase inhibitor, but filled neither.
We observed a strong inverse association between en-
docrine therapy use and age (Table 1). Comparedwithwomen
ages65–74years, those75andolderwere67%less likely touse
endocrine therapy (RR 0.33; 95% CI 0.13–0.82), and those
45–54were 69%more likely (RR 1.69; 95%CI 1.16–2.46).With
each 1-year increase in age at diagnosis, women were 3% less
likely to use endocrine therapy (RR 0.97; 95% CI 0.96–0.98)
(Table 1).
Endocrine therapy initiation was most common among
women who had BCS with radiation. Women with BCS with-
out radiation were 54% less likely to use endocrine therapy (RR
0.46; 95% CI 0.25–0.84), and women who had mastectomy
Table 1. Tumor registry characteristics among women with a ductal carcinoma in situ diagnosis in relation to use of endocrine
therapy, Group Health Cooperative, Seattle,WA, 1996–2011
Characteristic
Endocrine therapya No endocrine therapy
RR (95% CI)b RR (95% CI)cn % n %
Total 163 100 564 100 NA NA
Age at diagnosis, years
28–44 16 10 45 8 1.51 (0.88–2.59) 1.68 (0.97–2.90)
45–54 64 39 136 24 1.84 (1.24–2.72) 1.69 (1.16–2.46)
55–64 50 31 156 28 1.40 (0.92–2.11) 1.31 (0.88–1.95)
65–74 28 17 133 24 1 1
75–89 5 3 94 17 0.29 (0.12–0.73) 0.33 (0.13–0.82)
Continuous age at diagnosis 0.97 (0.96–0.98) 0.97 (0.96–0.98)
Race
White 135 82.8 494 87.6 1 1
Black 7 4.3 21 3.7 1.10 (0.51–2.35) 1.06 (0.56–2.00)
Asian/Pacific Islander 20 12.3 46 8.2 1.20 (0.75–1.93) 1.19 (0.82–1.74)
Other ,5 #2 ,5 #2
Estrogen receptor status
Negative ,5 #2 32 6 0.59 (0.22–1.57) 0.49 (0.18–1.32)
Positive 68 42 97 17 2.14 (1.65–2.77) 2.05 (1.53–2.74)
Unknown/not tested 91 56 435 77 1 1
Surgery and radiation
Breast-conserving surgery, no radiation 10 6 90 16 0.41 (0.23–0.75) 0.46 (0.25–0.84)
Breast-conserving surgery, radiationd 114 70 287 51 1 1
Mastectomy 37 23 185 33 0.57 (0.41–0.78) 0.54 (0.39–0.75)
Bilateral mastectomy ,5 #2 43 8
Tumor size, mm
#5 56 34 231 41 1 1
6–14 29 18 81 14 1.41 (0.96–2.08) 1.07 (0.75–1.54)
15–24 20 12 50 9 1.52 (0.99–2.34) 1.17 (0.76–1.80)
25–125 14 9 36 6 1.46 (0.90–2.38) 1.37 (0.83–2.28)
Microinvasion ,5 #2 8 1
Not documented 41 25 158 28
Per 5-mm increase in size 1.05 (1.01–1.10) 1.04 (0.99–1.09)
Grade
I–II: well to moderately differentiatede 35 21 149 26 1 1
III: poorly differentiated 121 74 348 62 1.34 (0.97–1.86) 1.49 (1.08–2.06)
Missing 7 4 67 12
Comedo status
No 152 93 479 85 1 1
Yes 11 7 85 15 0.48 (0.27–0.84) 0.62 (0.35–1.10)
aOne hundred forty-nine tamoxifen users plus 14 aromatase inhibitor users.
bAdjusted for age at diagnosis.
cAdjusted for age and calendar year at diagnosis, estrogen receptor status, surgery and radiation, tumor size, grade, and comedo status.
dIncludes 5 endocrine therapy users and 11 nonusers with radiation recommended but not known if received.
eIncludes 5 endocrine therapy users and 13 nonusers with grade I (well differentiated) disease.
Abbreviations: CI, confidence interval; NA, not applicable; RR, relative risk
©AlphaMed Press 2016
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(where radiation is generally not recommended for DCIS)
were 46% less likely (RR 0.54; 95% CI 0.39–0.75) compared
with women who had BCS and radiation. Overall, 6% of DCIS
cases (n 5 47) elected to have a contralateral prophylactic
mastectomy (Table 1).
We observed a positive trend between increasing tumor
size and endocrine therapy initiation that was of borderline
statistical significance: each 5-mm increase in tumor size cor-
responded to a 4% increase in endocrine therapy initiation
(RR 1.04; 95% CI 0.99–1.09). Compared with women with
grade I–II DCIS, women with grade III disease were 49% more
likely to use endocrine therapy (RR 1.49, 95% CI 1.08–2.06).
The presence of comedo necrosis appeared to be inversely
associated with endocrine therapy use in age-adjusted models;
the association was somewhat attenuated and not statistically
significant after full multivariable adjustment (RR 0.62; 95%
CI 0.35–1.10) (Table 1).
In our sample, ER testing was not commonly performed
(,10% of annual cases) before 2001. Over the most recent
decade of data (2001–2011), ER testing increased from 4%
of cases to 71% (data not shown). Women were less likely to
use endocrine therapy before the FDA’s approval of tamoxifen
for DCIS in 2000 (Table 2). Endocrine therapy use peaked
(27%) in 2001–2005 and then declined in subsequent years
(RR 0.66; 95% CI 0.46–0.94 in 2006–2008, and RR 0.68; 95%
CI 0.50–1.00 in 2009–2011). Figure 1 demonstrates that the
overall proportion of women who initiated endocrine therapy
did not correspond to rapid increases in ER testing during this
time (with subsequent identification of a higher proportion of
patients with ER1 disease). In fact, the steepest declines in endo-
crine therapy initiation were among women with documented
ER1DCIS: from58% in 2001–2005 to 37% in 2009–2011 (Fig. 1).
Women with some college education were more likely to
use endocrine therapy compared with women with a high
school diploma or less (RR 1.51; 95% CI 1.01–2.27); this
increase did not extend to women with formal education
beyond college (RR 1.23; 95% CI 0.82–1.84) (Table 2).We did
not observe statistically significant associations between body
mass index, cigarette smoking, hysterectomy status, or comor-
bidity index score. However, the point estimate for current
smoking compared with never smoking was suggestive of an
inverse association with endocrine therapy use (RR 0.62; 95%
CI 0.36–1.07) (Table 2).
Few endocrine therapy users (n5 7) had amedical history
of osteoporosis or fracture. Tamoxifen can be beneficial for
bone in postmenopausal women but detrimental before
menopause [21]. Information on menopausal status was not
available; however, all women who used endocrine therapy
after DCIS who had a medical history of osteoporosis or
fracture were aged 50 years and older at DCIS diagnosis.There
was no history of deep vein thrombosis, pulmonary embolism,
or stroke among endocrine therapy users (Table 2).
AIs are recommended as adjuvant breast cancer therapy
only for postmenopausal women; therefore, we repeated all
analyses excluding the 14 AI users, and results were very
similar. We also varied our definition of endocrine therapy
initiation from $1 fill of a tamoxifen or aromatase inhibitor
prescriptionwithin 12months after diagnosis to$2 fillswithin
12months of diagnosis; the associations presented here were
not substantially changed (data not shown).
DISCUSSION
The rapid increase in ER testing since tamoxifen’s approval in
2000 has not corresponded to increases in endocrine therapy
initiation, despite recognition of an increasing number of DCIS
tumors as ER1 each year. Furthermore, hysterectomy status,
bone health, and vascular clotting conditions at diagnosis [7,
22]—factors that influence the risk profile for tamoxifen
use—were not associated with endocrine therapy initiation
after DCIS. This may suggest that the factors that prompt
women and their providers to accept or prescribe tamoxifen
may be more analogous to the chemoprevention context, in
which perceived risk of future breast cancer is the most
consistently recognized driver of use [23], rather than the
invasive disease context, in which specific tumor characteris-
tics most often direct clinical decision making.
Although tamoxifen is currently the only FDA-approved
endocrine therapy for DCIS, aromatase inhibitors are currently
being evaluated in the NSABP B-35 trial [24, 25]. Results
presented at the 2015 American Society of Clinical Oncology
meeting showeda27%decrease in riskof secondbreastcancer
among women with ER1 or progesterone receptor-positive
DCIS randomized to anastrozole compared with tamoxifen
(HR 0.73; p 5 .03), with benefits most apparent in women
younger than 60 and in the later years of the study [26]. Last
year, the IBIS II trial reported an estimated 56% reduction
(HR 0.44; 95%CI 0.17–1.15) in future breast cancer risk among
postmenopausal women with a DCIS diagnosis randomized
to anastrozole compared with placebo [27]. This is similar to
the HR of 0.47 for invasive and in situ breast cancer reported
in the exemestane arm of the Mammary Prevention.3 trial
compared with placebo, which included women with DCIS
treated with mastectomy (n 5 112) [28]. In our study, we
included women who used an aromatase inhibitor after DCIS
diagnosis as endocrine therapy users to capture potential
off-label use. Aromatase inhibitors made up 9% of en-
docrine therapy initiation after DCIS. This is similar to the 12%
aromatase inhibitor use (anastrozole and letrozole) reported
among endocrine therapy users$18 years old across California
Cancer Registry regions during an overlapping time period [29].
Figure 1. ET initiation and ER testing of DCIS by calendar period,
Group Health Cooperative, 1996–2011.
Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen
receptor; ET, endocrine therapy; Unk, unknown.
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We hypothesized that endocrine therapy initiation would
be more common among women who underwent BCS as an
alternative to radiation or mastectomy. Instead, we observed
that women who had BCS with radiation were most likely to
initiate endocrine therapy. Nakhlis et al. reported that a higher
proportion of womenwho had BCS used tamoxifen compared
with women who had a mastectomy after DCIS (80% vs. 46%;
p 5 .002) at the Lynn Sage Breast Center in Chicago during
1998–2001; radiation therapy was not evaluated [30]. The
association between primary DCIS treatment and endocrine
therapy use reported by Livaudais et al. was not statistically
significant, but in the same direction as our own: compared
with mastectomy, women who reported BCS with radiation
were more likely to use endocrine therapy (odds ratio [OR]
1.34; 95% CI 0.77–2.31 across eight California Cancer Registry
regions during 2002–2005) [29].
Our study supports an inverse association between
endocrine therapy initiation and age at DCIS diagnosis, similar
Table2. Calendar yearofdiagnosis andmedical historyamongwomenwithductal carcinoma in situ in relation touseofendocrine
therapy, Group Health Cooperative, Seattle,WA, 1996–2011
Characteristic
Endocrine therapy (n5163)a Noendocrine therapy (n5564)
RR (95% CI)b RR (95% CI)cn % n %
Calendar year of diagnosis
1996–2000 26 16 181 32 0.45 (0.30–0.67) 0.60 (0.39–0.93)
2001–2005 66 40 171 30 1 1
2006–2008 34 21 106 19 0.86 (0.60–1.22) 0.66 (0.46–0.94)
2009–2011 37 23 106 19 0.98 (0.70–1.37) 0.68 (0.50–1.00)
Education
High school or less 20 12 127 23 1 1
Some college 65 40 179 32 1.56 (1.03–2.36) 1.51 (1.01–2.27)
College or more 74 45 242 43 1.25 (0.82–1.90) 1.23 (0.82–1.84)
Unknown ,5 #2 16 3
Body mass index, kg/m2
,18.5 ,5 #2 9 2 Excluded Excluded
18.5–24.9 61 37 222 39 1 1
25.0–29.9 50 31 171 30 1.08 (0.78–1.49) 0.98 (0.72–1.35)
$30.0 50 31 154 27 1.22 (0.88–1.69) 1.09 (0.80–1.49)
Missing 0 0 8 1
Smoking
Never 106 65 332 59 1 1
Former 47 29 171 30 0.90 (0.67–1.22) 0.89 (0.68–1.18)
Current 10 6 49 9 0.67 (0.37–1.19) 0.62 (0.36–1.07)
Missing 0 0 12 2
Hysterectomy before diagnosis
No 119 73 399 71 1 1
Yes 33 20 153 27 1.00 (0.71–1.43) 1.02 (0.72–1.44)
Missing 11 7 12 2
Comorbidity index
0 136 83 439 78 1 1
1 21 13 80 14 1.10 (0.73–1.65) 1.25 (0.84–1.84)
2 6 4 45 8 0.83 (0.39–1.76) 0.95 (0.46–1.93)
Osteoporosis or fracture
No 156 96 534 95 1 1
Yes 7 4 30 5 1.10 (0.55–2.19) 1.07 (0.56–2.02)
Deep vein thrombosis, pulmonary
embolism, or stroke
No 163 100 554 98 1 1
Yes 0 0 10 2 Not calculated Not calculated
aOne hundred forty-nine tamoxifen users plus 14 aromatase inhibitor users.
bAdjusted for age at diagnosis.
cAdjusted for age and calendar year at diagnosis, education, estrogen receptor status, surgery and radiation, tumor size, and grade.
Abbreviations: CI, confidence interval; RR, relative risk.
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tomost [31–33], but not all [29], prior reports. Consistentwith
our results, a large increase in tamoxifen use, leading to its
approval as adjuvant therapy for DCIS in 2000, was reported
across three integrated health care delivery systems during
1990–2001 [32, 34] and a population-based cohort of women
with DCIS in Wisconsin during 1995–2003 [35]. Also like our
findings, tamoxifen use in the Wisconsin cohort subsequently
decreased slightly between 2001–2003 and 2004–2006 [35].
Previous studies reported conflicting results on the as-
sociation between education level and use of endocrine
therapy. In our data, women with more education appeared
more likely to initiate endocrine therapy. However, in two
other studies, educational level was not associated with
tamoxifen use after DCIS [29, 32]. In a third report, Kaiser
Permanente members residing in census tracts with the
highest proportion of college-educated residents appeared
less likely touseendocrine therapy (OR0.81;95%CI0.69–0.94)
compared with the lowest quintile. Our results for grade and
comorbidity index also differ from those reported across six
Kaiser Systems where Charlson score $2 (compared with
0,OR0.76; 95%CI 0.64–0.91) andhigh-gradedisease (compared
with low/intermediategrade,OR0.83; 95%CI0.76–0.92)were
associated with lower levels of endocrine therapy use [33].
Across six Kaiser Permanente regions during 2001–2011,
African American womenwere less likely to initiate endocrine
therapy (OR 0.82; 95% CI 0.70–0.96), and Asian women were
more likely (OR 1.18; 95% CI 1.03–1.34), compared with white
women [33]. Our analysis was limited by small sample sizes;
however, the estimate for endocrine therapy initiation among
Asianwomen (n5 66) comparedwith white women (RR 1.19;
95% CI 0.82–1.74) was similar to that reported in the Kaiser
sites. Lower levels of endocrine therapy initiation among
AfricanAmericancomparedwithwhitewomenwithDCISwere
observed at the Detroit Medical Center/Karmanos Cancer
Institute in Michigan during 1996–2000 [36]. Conversely, in
an analysis of women seen at the MD Anderson Cancer
Center (Houston, TX) during 1996–2009, white patients
diagnosed with DCIS were less likely to receive adjuvant
therapy with tamoxifen than Asian/Pacific Islander and
AfricanAmericanwomen [37].Twoother studies reportedno
association between race and tamoxifen initiation after DCIS
[31, 32].
Most previous reports have not had information available
on ER status [32, 33, 36], which could influence associations if
ER status of DCIS tumors varies according to race or grade [33].
Our statistical models adjusted for ER status; however, in
models that did not include ER status as a covariate, the
interpretation of race and grade associations was unchanged.
Oneprevious reportusingdatafromtheNorthCarolinaCentral
Cancer Registry observed no association between ER status
and endocrine therapy initiation in 1998–1999; however, ER
testing was not performed for 85% of DCIS diagnoses [31]. ER
status was not associated with tamoxifen use in an analysis of
women treated for DCIS at the Lynn Sage Breast Center in
Chicago during 1998–2001 [30].
Strengths of our study included detailed medical history
information rarely available in registry-based studies and a
15-yearwindow toevaluate trends in ER testingandendocrine
therapy initiation forDCIS. Limitationsofouranalysismustalso
be considered. We had no information on physician recom-
mendations or discussion about endocrine therapy to identify
women who may have declined offered therapy. Information
on BRCA1/2 mutation testing or family history was also not
available; however, in prior reports [30, 32], family history of
breast cancer was not related to tamoxifen use.
CONCLUSION
Endocrine therapy initiationwasmore common among young
women and did not appear to be used in place of radiation.
Womenwith higher-grade tumorswere alsomore likely to use
endocrine therapy; however, other indicators of potential
disease aggressiveness—such as comedo-type DCIS—were
not associated with initiation. Despite the widespread adop-
tion of ER testing for DCIS since 2000, uptake of endocrine
therapy did not increase during this period. Women with a
prior DCIS diagnosis are included in chemoprevention clinical
trials as a high-risk population for second breast cancers
[27, 28]. Controversy around the best clinicalmanagement of
women with DCIS [38] suggests that many of the same
difficultiesmayexist forwomenandproviders in determining
the best course of therapy after DCIS, including endocrine
therapy for secondary chemoprevention, as for high-risk
women without a prior breast cancer diagnosis.
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